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Abstract: Irisin, an adipomiokine known as a mediator of physical activity, induces the browning 
of adipose tissue and it has potentially protective properties in the development of obesity-related 
states, such as insulin resistance, arteriosclerosis, and type 2 diabetes. Despite numerous studies 
conducted on this factor, still little is known about its impact on the functioning of immunocompetent 
cells, but its potential anti-inflammatory properties were previously suggested. In the current study 
we investigated the role of irisin (0-100 nM) in the downstream pathway activation of Toll-like 
receptor 4 (TLR4) in RAW 264.7 macrophages stimulated with lipopolysaccharide (LPS; 100 ng/m L). 
The results have shown that irisin in high concentrations (50,100 nM) significantly decreased the 
TLR4 and MyD88 protein levels, as well as the phosphorylation of nuclear factor- kB (N F-kB), 
consequently leading to the reduction in the release of crucial pro-inflammatory cytokines. The 
above was confirmed for interleukin 1p (IL-1p), tumor necrosis factor a  (TNFa), interleukin 6 (IL-6), 
keratinocyte chemoattractant (KC), monocyte chemotactic protein 1 (MCP-1), as well as for high 
mobility group box 1 (HMGB1). Moreover, our results indicate that this effect is connected with 
irisin's impact on the phosphorylation of mitogen-activated protein kinases (MAPKs), where a 
significant reduction in p-JNK and p-ERK but not p-p38 was observed. In conclusion, these data 
suggest that irisin has potentially anti-inflammatory properties connected with the downregulation 
of downstream pathways of TLR4/M yD88.
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1. Introduction
Exercise-driven activity of skeletal muscles leads to a release of low-molecular-mass proteins 
called myokines [1]. Irisin is a part of the muscle secretome and it is formed by the proteolytic cleavage 
of the membrane-bound fibronectin type III domain containing five proteins (FNDC5) [2- 4]. Irisin 
plays a pleiotropic role in the metabolism [5] . It acts through autocrine and endocrine signaling [6] . 
The main endocrine targets for irisin are adipocytes residing in white adipose tissue (WAT) [7] . It has 
been well documented that irisin regulates adipose tissue-mediated thermogenesis [8] and induces 
the browning of WAT [9- 11], resulting in loss of body weight [10]. Irisin was also found to be secreted 
by adipocytes in a rat [12,13] or mouse model, as well as by human adipose tissue [14].
A sedentary lifestyle accompanied by an energy over-consumption is one of the major reasons for 
overweight and obesity. This state is associated with the activation of pro-inflammatory pathways and
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consequently can lead to the development of insulin resistance or other metabolic diseases [15]. 
Moreover, excessive fat accumulation in adipose tissue is defined as the main reason for the 
development of obesity-related mild inflammation which, in turn, plays a key role in the development 
of obesity-associated diseases. The adipose tissue is infiltrated with various types of immunocompetent 
cells, most of which are adipose tissue macrophages (ATMs) [16,17], the main source of inflammatory 
factors in adipose tissue. The accumulation of fat is accompanied by an increase in the ATM number 
and consequently leads to the enhancement of ongoing inflammation via the induction of inflammatory 
cytokine release by both ATMs as well as by adipocytes [18- 23].
Although there is no doubt that myokine secretion plays an important role in the pro- and 
anti-inflammatory balance in the adipose tissue, some aspects of irisin activity still remain unclear. 
As far as we know, irisin's impact the inflammatory response of macrophages has not yet been 
explained. In our previous work we have shown that its action intensifies phagocytosis but at the 
same time reduces the respiratory burst generated by macrophages [24]. A detailed characteristic 
of its immunomodulatory role seems to be especially important for the development of therapeutic 
strategies against low-grade inflammation generated by immunocompetent cells in adipose tissue. 
Our recent study has demonstrated that irisin significantly downregulates the pro-inflammatory 
activity of adipocytes (the manuscript under review); therefore, the aim of the present study 
was to assess the influence of irisin on macrophages. Particular attention has been paid to the 
activation of the downstream pathway of Toll-like receptor 4 (TLR4) and the release of crucial 
pro-inflammatory cytokines.
2. Results
2.1. Irisin Protects Macrophages against Lipopolysaccharide-Induced Injury
As the first step of our examination, we tested the effects of irisin preincubation on macrophage 
viability after LPS stimulation. As shown in Figure 1A, LPS at a dose of 100 ng/m L markedly increased 
the percentage of apoptotic macrophages, which was evaluated cytometrically with the Annexin V kit, 
but irisin pretreatment in high concentration (100 nM) significantly reduced these effects (p <  0.05). 
This observation has been confirmed in the MTT test, allowing us to assess the overall cell viability 
and activity (Figure 1B). Moreover, lower irisin concentrations (10 and 50 nM) were ineffective in both 
tests. We did not observe any significant influence of irisin pretreatment on the viability of quiescent 
macrophages, but our results suggest that a high irisin concentration can protect macrophages against 
LPS-induced injury.
2.2. Irisin Has an Impact on TLR4 Expression
Taking into account the Toll-like receptor 4 (TLR4) involvement in LPS recognition by 
macrophages, we evaluated the effects of irisin pretreatment on both TLR4 expression in quiescent 
as well as in LPS-activated macrophages. As presented in Figure 2 (bars), a 24 h pretreatment 
of quiescent macrophages with a lower irisin concentration (10 nM) intensified the TLR4 mRNA 
expression (p < 0.05), while higher doses of irisin (50 and 100 nM) were ineffective. These observations 
were confirmed by cytometric analysis of protein expression quantified after a 24 h preincubation with 
and without irisin. As presented in Figure 2  (lines), the level of the TLR4 protein was significantly 
elevated only in the group pretreated with irisin at a low concentration (10 nM; p < 0.05).
Moreover, the analysis of TLR4 expressions after LPS stimulation indicated a lack of impact on the 
mRNA expression after pretreatment with irisin, which was presented in Figure 2 (bars). Nevertheless, 
a cytometric analysis of the TLR4 protein expression showed a significant reduction in TLR4 protein 
expression after a high-dose irisin treatment (Figure 2; lines) compared with the control group (0 nM; 
p < 0.05). Pretreatment of macrophages with the lower irisin concentration (10 nM) had no impact on 
the TLR4 mRNA as well as the protein expression after LPS stimulation. These results showed that a 
low irisin concentration could potentially improve properties of quiescent macrophages associated
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with pathogen recognition by the elevation of TLR4 expression. Moreover, our data suggested that 
a higher irisin concentration, when acting upon the state of macrophage activation, reduced the 
exp ress ion of the TLR4 protein.
Figure 1. Protective effecis of irisin (IR) pretreatment on lipopoiysaccharide (LPS)-stimulated 
maccophage RAW 264.7 ceils. The cells were pfe-incubated with "various doses off irisin (O-WO nM) 
for 24 h, and after that stimukted with LPS (100 ng/m l,) for the next 24 h. Cehs v̂ iaboility-̂  was tested 
cytomefricaUy using an Annexin V kit: (A), where tlte results are presented as a mean percentage of late 
apoptotic croUd bars) or early apoptotic cells (open bars) ±  S.E. or colorimetrically in tthe 3-(4,5-dimethyl 
thiazol-2-yl)-2:5-diphenyl tefoazolium bromide (MTT) test (B), where the results ore presented as a 
mean percentage "vs. IRO group. The lne within the bers shows the general leve1 of apoptosis measured 
after 2/1 ha whhout LPS stimulation. N = four to five indep endent experimente. Statistical significances 
were dete rmined with the ANOVA with Tukey post hoc analysis. * °  < 0.05 significance compared with 
the control group lor early apoptosis intensity or ovhrall vfability; # pi < 0.05 significance rompaaed 
with the c ontrol group for late ipoptosis intensity.
Figure 12. Effects o f irisin pretreatment (UR; 0-100 nM) on Toll-like receptor 4 (TLR4) expression on 
mRNA and protein level. Macrophages RAW 264.7, preheated with irisin for 24 h, were cultured with 
and without LPS (100 ng/mL) for an additienal 6 h (mRNA expression; rtPCR; bars) err 24 h (protein 
expression; cytometer; lines). Protein level was expressed as a peccentage vs. rontrol group (0 nM) as 
100%. Control groups—IRO with or without (w/o) LPS. Tire results are expressed as means + SE of 
four tor five independent experiments (# 1 < 0.05 significance compared with control group) for mRNAs 
expression; * p <  0.05 signifecance compared with controt group for protein expression). Statistical 
signifecances were derermined with the ANOVA with Tukey post hoc analysis.
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2.3. Irisin Regulates the Downstream Pathway o f TLR4IMyD80
Next, we evaluated the downstream pathway of TLR4 to verify the effects of irisin pretreatment 
on the signaling cascade activation and pro-inflammatory mediators released by LPS-stimulated 
macrophages. As presented in Figure 3A, macrophages pretreated with a high irisin concentration 
(100 nM) manifested significantly less MyD88 expression (p < 0.05) compared with control cells (0 nM). 
Irisin (100 nM) reduced the MyD88 level by nearly 37%, while lower irisin concentrations (10 and 
50 nM) induced a slight effect (p =  0.05 for 50 nM, and p > 0.05 for 10 nM).
Figure 3. Irisin inhibits the downstream pathway of TLR4/MyD88 in macrophages activated with 
LPS. RAW 264.7 macrophages were cultured with various irisin concentrations (IR; 0-100 nM) for 
24 h and then stimulated with LPS (100 ng/mL). The relative protein levels of MyD88 (A); nuclear 
factor-KB (NF-kB) (B), JNK (C), ERK (D) and pf8 mitogen-activated protein kinases (MAPK) (E) -were 
evalu6ted cytometrically and expressed as a percentage vs. control group (irisin 0 nM) presented as a 
100°/o . N  = four independent experiments. Statistical significances were determined with the ANOVA 
with Tukey post hoc analysis. * p < 0.0f significance compared with control group.
Moreover, analysis of the phosphorylation of the crucial components of the TLR4 pathway 
indicated that the irisin pretreatment resulted in the downregulation of MAPK signaling pathweys 
(Figure 3C-E ) and conaequently reduced the nuclear factor-KB (NF-kB) activation by 39% (p < 0.01; 
Figure 3B). Particularly, the phosphorylation of JNK and ERK but not p38 kinase was decreased after 
macrophages were pretreated with a high irisin concentration 1100 nM), and the levels were lowered 
by abouO 21%, and 34%, respectively (p < 0.05). Lower doses of iris-n (up to 50 nM) have only a  slight 
impact on kinase phosphorylation (p =  0.05 o r p >  0.05), but after macrophages wero pretreated with 
irisin at 50 nM, at reduction in NF-kB activation was alao observed (2118; p <  e.05). The lowest irisfn 
concentration (10 nM) had no impact on both the kinases and NF-kB phosphorylation (p > 0.05).
2.4. Irisin Pretreatment Reduces the Level o f Pro-Inflammatory Cytokines
The last step. in our investigation was the evaluation of cytokine/chem okine expression and 
secretion after pretreahnent with irisin. Macrophages stimulated with LPS markedly incteased both 
the cytekine mRNA expression as well as the cytokine release measured after 24 h of stimulation 
(Figure 4) . Moreover, a 24 h pretreatment of macrophages with ir(sin in a dose-dependent manner 
reduced both the mRNA expression and secretion of TN Fa, IL-1p, IL-6, MCP-1, KC and HMGB1. 
As presented in Figure 4A, higher irisin concentrations (100 and 50 nM) effectively reduced the TN Fa 
mRNA expression by 45% and 22%, and the TN Fa release by 40% and 18%, respectively (p <  0.01).
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In the case of IL-6, the mRNA level was lower— about 51% (100 nM) and 35% (50 nM)— while the 
cytokine content in the supernatant was reduced by 36% and 27%, respectively (p <  0.05; F igure4B). 
The mRNA level of IL-1ß was reduced by 79% by irisin at 100 nM, and by 52% by irisin at 50 nM 
(p <  0.001; Figure 4C). The level of IL-1ß reteased was decreased respectively by 62% and 45%o in 
comparison with tire; control group (0 nM; p <  0.01). Moreover, higher irisin concentrations (100 and 
50 nM) effectively reduced MCp-1 mRNA expression by 80%, and 56%, respective^, which was 
accompanied by the lowering of MCP-1 secretion by 46% and 30%, respectively (Figure 4D).
Figure 4. Irisin reduces pro-inflammatory cytokines expression and secretion by LPS-activated 
macrophages. Macrophage RAW 264.7 cells were pretreated for 24 h with irisin (IR; 0-100 nM) 
and then stimulated with LPS (100 ng/m L) for 4 h (mRNA expression; rtPCR) or 24 h (cytokine 
release; ELISA tests). Relative mRNA expression (bars) and protein secretion (lines) of tumor necrosis 
factor alpha (TNFa) (A), interleukin 6 (IL-6) (B), interleukin 1|3 (IL-1|3) (C), monocyte chemotactic 
protein 1 (MCP-1) (D), keratinocyte chemoatteactant (KC) (E), and high mobility group box 1 (HMGB1) 
(F) were assessed. CTR—non-stimulated group, quiescent macrophages. The results are expressed 
as means ±  SE of four to five independent experiments (* p <  0.05 significance compared with IR0 
group for mRNA expression; # p < 0.05 significance compared with IR0 group for cytokine release to 
supernatant). Statistical significances were determined with the ANOVA with Tukey post hoc analysis.
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Furthermore, the analysis of KC distribution in RAW 264.7 macrophages indicated that high 
irisin concentrations (100 and 50 nM) markedly inhibited the KC mRNA expression by 65% and 33%, 
respectively (p <  0.01), and consequently reduced the level of KC released upon LPS stimulation by 
52% (p < 0.01) and 28% (p < 0.05; Figure 4E).
The effect of irisin on HMGB1 expression was not so prominent (Figure 4F), but irisin at a 100 nM 
concentration significantly reduced both the mRNA and cytokine levels by 28% and 20%, respectively 
(p  <  0.05). In all cases, the lowest irisin concentration (10 nM) did not diminish the level of tested 
cytokines (p > 0.05). Moreover, quantification of mRNA levels in quiescent macrophages indicated that 
the rest levels of TN Fa and IL-1|3 mRNA expression are downregulated in macrophages pre-incubated 
with irisin (100 nM) for 24 h, when compared to control cells (0 nM; p < 0.05).
3. Discussion
Irisin is a peptide that has been widely investigated in the recent years. Numerous studies 
highlight the beneficial and protective properties of irisin level elevation in obesity, insulin resistance, 
metabolic disorders [25- 27] and hepatic steatosis [28]. Moreover, data show that the irisin plasma 
level may be a predictive factor for such conditions as diabetes mellitus 2 [29], cardiometabolic risk in 
sedentary lifestyles [30], sarcopenia and carotid arteriosclerosis [31], chronic kidney diseases [32], 
polycystic ovary syndrome [33] or breast cancer [34]. As reported by Rana et al. [35], irisin 
level correlated with the patient's age may predict telomere length. Repeatedly, studies also 
indicated a correlation between the irisin level and the level of inflammatory factors, suggesting 
its anti-inflammatory properties [36,37]. Nevertheless, there is still little evidence to explain the direct 
effect of irisin on the activation of immunocompetent cells [38]. Therefore, research on the mechanisms 
of action of irisin is particularly needed.
Macrophages, as crucial cells in the first line of our immune defense, play an important role in 
pathogen elimination and the recruitment of other cells to the place of ongoing inflammation. However, 
in some pathological conditions, such as, for example, obesity, their excessive activation can lead 
to the induction of mild inflammation and consequently to associated disease development. In the 
mechanism of pathogen recognition, a prominent role is assigned to Toll-like receptors (TLRs) which 
are stimulated by pathogen-associated molecular patterns (PAMPs) as a typical structural motif of 
bacteria, viruses or fungi [39]. LPS, a component of the outer membrane of Gram-negative bacteria, as 
a PAMP interacts with the TLR4 receptor and triggers the downstream pathway activation, leading to 
phosphorylation and translocation of the transcription factor N F-kB, and consequently the secretion 
of pro-inflammatory mediators [40]. The downstream TLR4 pathway, through interaction of several 
protein complexes, leads to the activation of the MyD88-dependent or MyD88-independent pathways 
and consequently to pro-inflammatory cytokines or interferon type I being released, respectively [39]. 
At this point we should pay attention to two aspects analyzed in this work; firstly on irisin's influence 
on resting macrophages, and secondly on macrophages stimulated by LPS. Analysis performed on 
quiescent cells indicated that the pretreatment of macrophages with a low irisin concentration results 
in the enhancement of TLR4 expression, which may suggest the increased ability of macrophages 
to recognize potential pathogens. However, it should be taken into account that TLR4 is a highly 
glycosylated protein which affects its functionality in terms of LPS recognition [41]. Our next studies 
suggest that irisin's influence on glycosylation and the formation of TLR4 glycoforms are possible 
(study under development). However, further studies are needed to explain and verify these aspects. 
Moreover, diminished release of TN Fa and IL-1p in the resting stage should also be emphasized. 
Other analyzed factors were not significantly different, but the reduction of TN Fa and IL-1p release 
draws attention to a potential reduction in the spontaneous pro-inflammatory activity of these cells. 
Our previous study [25] indicated, moreover, that irisin enhances macrophage proliferation and has 
a positive impact on the phagocytosis of bacteria while also inhibiting respiratory burst generation. 
In the state of macrophage activation by LPS stimulation, irisin pretreatment induced prominent 
anti-inflammatory effects, closely connected with the TLR4/M yD 88 downstream pathways. We
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observed a dose-dependent reduction in TLR4 protein expression after irisin pretreatment, which 
was accompanied by a reduction in the MyD88 level. It should be noted that the TLR4/M yD 88 
pathway activates signaling such as the mitogen-activated protein kinase (MAPK) pathway as well 
as the N F-kB pathway. This study indicates that irisin modulates both the activation of N F-kB and 
the MAPK pathway, leading to a reduction in the phosphorylation of the mentioned factors. The 
anti-inflammatory effect of the irisin pretreatment, suggested in this paper, was manifested mainly by 
the lowering of the expression and secretion of key inflammatory cytokines. We observed a reduction 
in TNFa, IL-1 p, IL-6, MCP-1, KC and HMGB1 levels, which can be explained by the above-mentioned 
inhibition of the TLR4/M yD 88 pathway. Irisin's impact on the inhibition of TN Fa, IL-1p, and IL-6 
was previously mentioned by Dong et al. [38], who also noted the promotion of the alternative 
polarization of macrophages undergoing irisin stimulation. Moreover, our study demonstrated that 
irisin inhibits the expression and release of HMGB1, a nuclear DNA-binding protein which can be 
actively secreted by stimulated macrophages, or passively by damaged or necrotic cells [42]. As a 
late mediator of inflammation, HMGB1 induces an LPS-independent activation of N F-kB [43] and 
consequently enhances the secretion of pro-inflammatory factors, including TN Fa. Because of the 
HMGB1 action, amplification of the inflammatory response could be observed [44]. In our study, the 
level of HMGB1 was effectively reduced by a high irisin concentration, but the mechanisms of this 
inhibition should be examined in the future.
In conclusion, as presented in our study, irisin alleviates the inflammatory activation of 
macrophages stimulated by LPS. The anti-inflammatory effect of irisin, observed in this study, is 
mediated by inhibition of the downstream pathway of TLR4/M yD 88, which is connected with the 
suppressed phosphorylation of MAPK and consequently a lower N F-kB activation. As a result of 
these changes, we observed the reduction in both the expression and release of pro-inflammatory 
cytokines, such as IL-1 p, TNFa, IL-6, KC, MCP-1 and HMGB1. Our results may suggest that beneficial 
and anti-inflammatory properties of physical activity, as well as the potential protective effects of irisin 
against the development of diseases associated with obesity, may at least in part be associated with 
irisin's anti-inflammatory properties.
4. Materials and Methods
4.1. Chemicals and Materials
DMEM medium, antibiotics (streptomycin and penicillin), fetal bovine serum (FBS) were 
purchased from PAA (Pasching, Austria). Lipopolysaccharide (LPS) was purchased from 
Sigma-Aldrich (St. Louis, MO, USA). Irisin was purchased from Cayman. Annexin V kit, Fc block 
antibodies, Cytofix/Cytoperm  solution, PerCP-Cy5.5 streptavidin, Cytometric Bead Arrays for JNK, 
ERK and p38 quantification were acquired from BD Biosciences Pharmingen (San Diego, CA, USA). 
Phospho-NF-KB (ser536) Alexa Fluor 647 Conjugate rabbit monoclonal antibody was acquired from 
Cell Signaling Technology (Beverly, MA, USA). Elisa kit for HMGB1 and IL-1p were purchased from 
IBL International (Hamburg, Germany). RNeasy Plus Mini Kit (74134) for RNA isolation was obtained 
from Qiagen (Hilden, Germany). High Capacity RNA-to-cDNA Kit (4387406) for reverse transcription 
and TaqMan Gene Expresson Master Mix (4369026) for real time PCR were obtained from Applied 
Biosystems (ThermoFisher; Foster City, CA, USA).
4.2. Cell Culture and Experimental Design
The study was conducted on a murine macrophage-like RAW 264.7 cell line (European Type 
Culture Collection; ETCC, Sigma), free of mycoplasma contamination. The cells were cultured under 
standard conditions (37 °C, 5% CO2 ) in a DMEM medium supplemented with 1% of antibiotic, 10% 
of fetal bovine serum, and irisin (0-100 nM) for 24 h, and after that the cells were stimulated with 
LPS (100 n g/m L ; Escherichia coli, serotype 0111: B4). Fresh cells were used for MTT test, cytometric
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assessment and RNA isolation. Supernatants were frozen ( - 6 0  °C) for future quantification of
cytokine levels.
4.3. Colorimetric Examination o f  Overall Cell Viability
The total cell viability and activity was measured by assaying the reduction of 3-(4,5-dimethyl 
thiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) to formazan, according to the manufacturer's 
instruction and quantify on a spectrophotometer (Expert Plus, A SYS/Hitech, Eugendorf, Austria).
4.4. Quantitative Real-Time PCR Assay
Quantitative Real time PCR was used to assess TLR4, TN Fa, IL-1p, IL-6, MCP-1, KC and 
HMGB1 gene expression. RNA was extracted from RAW 264.7 cells using RNeasy Plus Mini Kit 
(Qiagen, 74134) and reverse transcription was carried out using the High Capacity RNA-to-cDNA 
Kit (Applied Biosystems, 4387406) according to the m anufacturer's protocols. Real time PCR was 
performed using TaqMan Gene Expresson Master Mix (Applied Biosystems, 4369026) in Step One 
Plus thermocycler (Applied Biosystems). The expression of analyzed genes was normalized to the 
expression level of glyceraldehyde-3-phosphate dehydrogenase (GAPDH) used as a housekeeping 
gene. mRNA expression of each sample was determined in four-five (separate RNA isolation) using 
the 2-AACt method.
4.5. Flow Cytometric Analysis
The irisin impact on macrophage apoptosis was determined using an Annexin V kit according 
to the protocol provided by the producer. For the analysis, 10,000 cells were acquired. Cells were 
previously pretreated with irisin (0-100 nM) for 24 h and subsequently with LPS (100 ng/m L ) for 
additional 24 h.
The level of MyD88 and NF-kB were detected by flow cytometry after labeling with a fluorescent 
antibody. Briefly, after a 24 h preincubation with irisin (0-100 nM), cells were stimulated with LPS for 
additional 24 h. After that, cells were detached, blocked with Fc-block (0.5 m g/m L; 1:200; 20 min; 4 °C), 
fixed, and permeabilized according to the manufacturer's instructions (Cytofix/Cytoperm) and treated 
with an appropriate antibody. For MyD88 detection, the biotin anti-MyD88 antibody (0.2 m g/m L; 
1:200; 20 min; 4 °C) and PerCP-Cy5.5 streptavidin (0.2 m g/m L ; 1:200; 20 min; 4 °C) were used; for 
the detection of the phosphorylated form of N F-kB, cells were stained with phosphor-NF-KB (Ser536) 
Alexa Fluor 647 Conjugate rabbit monoclonal antibody (0.1 m g/m L; 1:100; 20 min). All antigens were 
detected separately. For data analysis, 10,000 pre-labeled cells were collected.
The levels of the phosphorylated forms of kinases JNK, ERK and p38 were determined using a 
commercial Cytometric Bead Arrays according to the manufacturer's protocol.
All the samples were acquired and analyzed on a FACScan flow cytometer (FACSCaliburTM; 
BD Biosciences, San Diego, CA, USA) using CBA and CellQuest software (BD Biosciences, San Diego, 
CA, USA).
4.6. Elisa Examination o f Cytokine/Chemokine Release
The levels of such cytokine as TN Fa, IL-1p, IL-6, MCP-1, KC and HMGB1 were quantified 
using a commercial ELISA Kit, according to the m anufacturer's instruction and measured on a 
spectrophotometer (Expert Plus, A SY S/H itech, Eugendorf, Austria). All cytokines were measured 
separately in supernatants collected after 24 h of LPS stimulation.
4.7. Statistical Analysis
Data were tested for normality of the distribution, and differences among groups were determined 
using ANOVA with Tukey post hoc analysis. All data were expressed as means ±  standard error 
(X ±  SE) with the level of statistical significance (p) set at 0.05.
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Abbreviations
ATMs Adipose tissue macrophages
FNDC5 Fibronectin type III domain containing 5 protein
HMGB1 High mobility group box 1




MAPKs Mitogen-activated protein kinases
MCP-1 Monocyte chemotactic protein 1
MyD88 Myeloid differentiation primary response protein
NF-kB Nuclear factor-KB
p-ERK Phospho extracellular signal-regulated kinase
p-JNK Phospho c-Jun N-terminal kinase
TLR4 Toll-like receptor 4
TNFa Tumor necrosis factor a
WAT White adipose tissue
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